<DOC>
	<DOCNO>NCT01990300</DOCNO>
	<brief_summary>The purpose study examine safety efficacy long-term use alogliptin/pioglitazone ( Liovel ) combination tablet patient type 2 diabetes mellitus determine warrant combination therapy alogliptin benzoate pioglitazone hydrochloride</brief_summary>
	<brief_title>Alogliptin/Pioglitazone ( Liovel ) Liovel Combination Tablets Survey Long-term Use Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This special drug use surveillance long-term use alogliptin/pioglitazone combination tablet . This study design investigate safety efficacy long-term use alogliptin/pioglitazone combination tablet patient type 2 diabetes mellitus routine clinical setting . Participants patient type 2 diabetes mellitus . The planned sample size 3000 . The usual adult dosage 1 tablet ( contain alogliptin/pioglitazone either 25 mg/15 mg 25 mg/30 mg ) take orally daily breakfast .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Patients type 2 diabetes mellitus Patients meeting follow criterion exclude : 1 . Patients current cardiac failure past history cardiac failure 2 . Patients severe ketosis , diabetic coma precoma , type 1 diabetes mellitus 3 . Patients serious hepatic dysfunction 4 . Patients serious renal dysfunction 5 . Patients severe infection , pre postoperative patient , patient serious traumatic injury 6 . Patients history hypersensitivity ingredient Liovel 7 . Pregnant possibly pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>